FDA Apporoves 'Alhemo' to Help Hemophilia Patients Manage BleedingNovo Nordisk's hemophilia treatment Alhemo has FDA approval, targeting patients with antibodies against traditional therapies.
Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese AdultsNovo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use...
Novo Nordisk Confirms Weight Loss Effects, New Blockbuster for Obesity TreatmentAnalysts have suggested that Novo Nordisk (NVO) could have another potential blockbuster obesity treatment following Semaglutide, along with the clinical results of Amycretin (Amylin/GLP dual receptor). Novo Nordisk’s stock price rose 9% on the day it announced the phase 1 clinical results of Amycretin. This product uses the same oral platform technology SNAC as applied […]
Must-Reads
1
What’s Next for Nissan’s Iconic GT-R? The Hyper Force Concept Gives Us a Glimpse
BUSINESS
2
Tesla's Self-Driving Technology's Horrible Flaw: Self-Driving Vehicle on the Railroad Tracks
DEBATE
3
Tesla's Invasion of Privacy: Controversy Arises Over Sensitive Driver Data Sharing
DEBATE
4
North Korea Sends Young Volunteers to Dangerous Jobs Under the Guise of Voluntary Participation
ASIA
5
Tension Soars in South Korea’s Presidential Security: Arming Guards with Heavy Weapons After Resignation
FDA Apporoves 'Alhemo' to Help Hemophilia Patients Manage Bleeding Novo Nordisk's hemophilia treatment Alhemo has FDA approval, targeting patients with antibodies against traditional therapies.
Novo Nordisk’s Wegovy Approved in UK for Reducing Cardiovascular Risk in Obese Adults Novo Nordisk recently announced that its weight-loss drug, Wegovy, has been approved by UK regulatory authorities for use...
Novo Nordisk Confirms Weight Loss Effects, New Blockbuster for Obesity Treatment Analysts have suggested that Novo Nordisk (NVO) could have another potential blockbuster obesity treatment following Semaglutide, along with the clinical results of Amycretin (Amylin/GLP dual receptor). Novo Nordisk’s stock price rose 9% on the day it announced the phase 1 clinical results of Amycretin. This product uses the same oral platform technology SNAC as applied […]
Hot Topics